We are live on
!
Find out more
Bellevue Group Portfolio holdings
AUM
$4.75B
Turnover
23.84%
1-Year Est. Return
68.58%
This Fund
S&P 500
This Quarter
Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
(-20%)
Cap. Flow
-$834M
Cap. Flow
% of AUM
-19.85%
Top 10 Holdings %
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40
Avg Time Held
3.8
years
Top 10 Avg Time Held
2.6
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$203M |
| 2 |
Gilead Sciences
GILD
|
+$156M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$146M |
| 4 |
Amgen
AMGN
|
+$98.7M |
| 5 |
Viridian Therapeutics
VRDN
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$350M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$235M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$225M |
| 4 |
RNAM
Avidity Biosciences
RNAM
|
+$190M |
| 5 |
Amicus Therapeutics
FOLD
|
+$153M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.74% |
| 2 | Energy | 0.07% |
| 3 | Technology | 0.06% |
| 4 | Miscellaneous | 0.05% |
| 5 | Financials | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
176
iShares Russell 2000 ETF
IWM
$77.5B
| – | – |
-2,300
| Closed | -$566K | – |
|
177
lululemon athletica
LULU
$11.5B
| – | – |
-2,240
| Closed | -$465K | – |
|
178
Meta Platforms (Facebook)
META
$1.88T
| – | – |
-800
| Closed | -$528K | – |
|
179
Molina Healthcare
MOH
$11.1B
| – | – |
-46,626
| Closed | -$8.09M | – |
|
180
Moderna
MRNA
$94.4B
| – | – |
-7,711
| Closed | -$227K | – |
|
181
NeoGenomics
NEO
$2.22B
| – | – |
-278,286
| Closed | -$3.27M | – |
|
182
Intellia Therapeutics
NTLA
$1.59B
| – | – |
-2,978
| Closed | -$26.8K | – |
|
183
Oric Pharmaceuticals
ORIC
$1.32B
| – | – |
-9,706
| Closed | -$79.4K | – |
|
184
Planet Fitness
PLNT
$3.72B
| – | – |
-3,173
| Closed | -$344K | – |
|
185
Palantir
PLTR
$482B
| – | – |
-2,500
| Closed | -$444K | – |
|
186
uniQure
QURE
$1.56B
| – | – |
-4,763
| Closed | -$114K | – |
|
|
RNAM
187
DELISTED
Avidity Biosciences
RNAM
| – | – |
-2,630,969
| Closed | -$190M | – |
|
188
Roivant Sciences
ROIV
$24.6B
| – | – |
-108,039
| Closed | -$2.34M | – |
|
189
SI-BONE Inc
SIBN
$892M
| – | – |
-90,331
| Closed | -$1.78M | – |
|
190
Sanofi
SNY
$96.5B
| – | – |
-5,851
| Closed | -$284K | – |
|
191
Trevi Therapeutics
TRVI
$1.73B
| – | – |
-7,603
| Closed | -$95.2K | – |
|
192
Tyra Biosciences
TYRA
$1.31B
| – | – |
-3,143
| Closed | -$82.6K | – |
|
193
Viking Therapeutics
VKTX
$3.48B
| – | – |
-68,665
| Closed | -$2.42M | – |
|
194
BrightSpring Health Services
BTSG
$12.3B
| – | – |
-92,095
| Closed | -$3.45M | – |
|
195
Maze Therapeutics
MAZE
$1.53B
| – | – |
-887,708
| Closed | -$36.8M | – |
|
Similar funds
PTC
Bellevue Group's Q1 2026 Portfolio in Review
As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.
Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.
- Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
- Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
- Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
- Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
- Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
- Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
- Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.